Indian Generics, 2008-2012: The Growing Threat to

Westernised Markets

Published: January 2008

Metrics: 138 pages; 45 Charts/Tables

View Table of Contents (pdf)

View Brochure (pdf)

Purchase Online Securely with PayPal

Solution Graphics
PRICING

PURCHASE NOW

Single User License

£1,600.00/US$3,120.00

1-5 User License

£2,600.00/US$5,070.00

Enterprisewide License

 

£3,800.00/US$7,410.00

 

NB. Exchange rates vary. All US$ prices shown are approximations. UK£ sterling prices are base prices, where conversions vary on day of purchase due to exchange rate fluctuations.
   

 

Report Overview

Indian pharmaceutical companies are grabbing headlines on an almost daily basis and are increasingly carving out market shares for themselves in the US and many other markets around the world. Several leading Indian pharmaceutical companies have applied themselves to the challenge of entering Western markets with great success. These companies now present a very serious threat to the existing Western generic companies in their domestic markets as they take ever-larger market shares and increase the levels of competition.

The Challenge from Indian Generic Companies

Why has this challenge arisen - what advantages do Indian companies enjoy that enable them to compete so successfully with Western generic companies?

It is the purpose of this report to answer that question and to provide Western pharmaceutical companies and others that are interested by this phenomenon with some explanation of the background. It will also offer some guidance as to how companies might deal with what some see as a threat and others view as a welcome source of low-cost generics.

 

 
Report Audience

Clients include leading multinationals, specialty pharmaceutical companies, investment and consulting firms, and many others. Some of our clients include:

Allergan.....Bayer...........Catalyst Pharma...........Ferndale Labs

Ipsen........Acrux .. Pfizer.. ..Boston Consulting........ Cephalon.

Nycomed...........Solvay..........Organon. . ..Roche..... Schering

Galderm.......Boehringer ........Merck... .....BioTie Therapeutics

Cephalon...........Stiefel Labs.....Morgan Stanley.. ..MacSmith...

 

Essential Competitive Intelligence for Strategic Growth and Development

 

home | about us | research & analysis | spectra reports | conferences | contact us